← Altimmune, Inc. (ALT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Altimmune, Inc. (ALT)
Pharmaceutical Preparations · market cap $628M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Altimmune, Inc. (ALT) is a clinical-stage pharmaceutical company with a market cap of ~$546M and a share price of ~$2.81. Its lead asset ALT-801 is in Phase 2 for obesity/overweight, with pemvidutide in Phase 2 for alcohol use disorder (AUD) and NasoVAX in Phase 2 for influenza. The company carries ~$97.6M in cash, representing roughly 14 months of runway, against a consistent annual cash burn of ~$85-95M.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ALT-801 | Phase 2 | Obesity/Overweight |
| Pemvidutide | Phase 2 | Alcohol Use Disorder (AUD) |
| NasoVAX | Phase 2 | Influenza |
Price & technical context
3-month
-12.7%
6-month
-11.5%
12-month
-26.8%
52-wk range
$2.59–$6.18
vs 50-day MA
-10.6%
vs 200-day MA
-20.5%
Realized vol
70.0%
Max drawdown
-73.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.